Onkologie. 2015:9(6):282-286

Current options of chemoradiotherapy treatment in locally advanced rectal carcinoma

Igor Richter1, Josef Dvořák2, Jiří Bartoš1, Peter Hromádka3, Jiří Škach3
1 Onkologické oddělení, Krajská nemocnice Liberec a.s., Liberec
2 Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
3 Chirurgické centrum, Krajská nemocnice Liberec, a.s., Liberec

The standard treatment of locally advanced rectal carcinoma is neoadjuvant chemotherapy followed by total mesorectal excision.

Neoadjuvant chemoradiotherapy has demostrated lower incidence of local recurrence and better profile of toxicity then adjuvant

chemoradiotherapy. The next article presents current view on treatment options, controversial issues and used the targeted treatment

in locally advanced rectal carcinoma.

Keywords: rectal carcinoma, radiotherapy, chemotherapy, targeted treatment

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richter I, Dvořák J, Bartoš J, Hromádka P, Škach J. Current options of chemoradiotherapy treatment in locally advanced rectal carcinoma. Onkologie. 2015;9(6):282-286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Doleželová-Horová H, Ondrová B, Šlampa P, et al. Karcinom konečníku s. 153-162. In: Šlampa P, Petera J, et al. Radiační onkologie. Nakladatelství Galén Praha; Nakladatelství Karolinum Praha; 2007; 1: 457.
    2. Kocáková I, Soumarová R. Chemoradioterapie karcinomu konečníku s 62-72. In: Šlampa P, Soumarová R, Kocáková I et al. Konkomitantní chemoradioterapie solidních nádorů. Nakladatelství Galén 2005: 167.
    3. Dvořák J, Richter I, Buka D, et al. Chemoradioterapie lokálně pokročilých karcinomů rekta. Kolorektální karcinom 2013, Farmakoterapie suppl. 2013: 42-46.
    4. Gray R, Hills R, Stowe R, et al. Adjuvant radiotherapy for rectal cancer: a systemic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304. Go to original source... Go to PubMed...
    5. Šlampa P, Lovas P. Současný pohled na chemoradioterapii karcinomu rekta. Kolorektální karcinom 2009, Farmakoterapie suppl. 2009: 44-49.
    6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740. Go to original source... Go to PubMed...
    7. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-up of 11 Years. J Clin Oncol 2012; 30: 1926-1933. Go to original source... Go to PubMed...
    8. Šlampa P, Lovas P, Lovasová Z, et al. Karcinomy konečníku s 70-78. In: Šlampa P a kol.: Radiační onkologie v praxi. Masarykův onkologický ústav Brno; 2011; 3: 319.
    9. De Caluwé L, van Nieuwenhove Y, Ceelen WP, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013; 2: CD006041 Go to original source... Go to PubMed...
    10. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123. Go to original source... Go to PubMed...
    11. Boulis-Wassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the european Organization on Research and Treatment of Cancer Gastroninestinal Tract Cancer Group. Cancer 1984; 53: 1811-1818. Go to original source... Go to PubMed...
    12. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. EORTC Radiotherapy Group Trial 22921. N Eng J Med 2006; 355: 1114-1123 Erratum in: N Engl J Med 2007; 357: 728. Go to original source... Go to PubMed...
    13. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorine in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625. Go to original source... Go to PubMed...
    14. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223. Go to original source... Go to PubMed...
    15. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patiens with rectal cancer: results of the MERCURY study. Radiology 2007; 243: 132-139. Go to original source... Go to PubMed...
    16. Glimelius B, Tiret E, Arnold D. Rectal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013; 24(Suppl 6): vi81-vi88. Go to original source... Go to PubMed...
    17. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postpostoperative chemotherapy with fluorouracil and oxaliplatine versus fluorouracil alone in locally advanced rectal cancer: initial results of German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687. Go to original source... Go to PubMed...
    18. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncol Group Trial 0012. J Clin Oncol 2006; 20: 519-524. Go to original source... Go to PubMed...
    19. Chan AK, Wong A, Jenken D, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 665-677. Go to original source... Go to PubMed...
    20. de Campos-Lobato LF, Stocchi L, da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011; 18: 1590-1598. Go to original source... Go to PubMed...
    21. Garcia-Aguilar J, Smith DD, Avila K, et al. Timing of rectal cancer response to chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254: 97-102. Go to original source... Go to PubMed...
    22. Smith KD, Tan D, Das P, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 2010; 251: 261-264. Go to original source... Go to PubMed...
    23. Hartley A, Ho KF, McConkey C, et al. Pathological complete response following preoperative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005; 78: 934-938. Go to original source... Go to PubMed...
    24. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response rate to neoadjuvant chemoradiotherapy for rectal cancer. Brit J of Surg 2012; 99: 918-928. Go to original source... Go to PubMed...
    25. Pucciarelli S, Troppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to Lower rectal cancer is not a prognostic factor a better outcomes. Dis Colon Rectum 2004; 47: 1998-1807. Go to original source... Go to PubMed...
    26. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathological complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol biol Phys 2008; 72: 99-107. Go to original source... Go to PubMed...
    27. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcomes in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844. Go to original source... Go to PubMed...
    28. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonooperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-717. Go to original source... Go to PubMed...
    29. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of silure and survival for nonoperative treatment of stage cO distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointes Sur 2006; 10: 1319-1328. Go to original source... Go to PubMed...
    30. Smith JJ, Chow OS, Eaton A, et al. Organ preservativ in patiens with rectal cancer with clinical komplete response after neoadjuvant therapy. 2015 ASCO Gastrointestinal Cancers Symposium. Abstract 509. Go to original source...
    31. Sloothaak DAM, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and Surgery for rectal cancer. Brit J of Surg 2013; 100: 933-939. Go to original source... Go to PubMed...
    32. Francois Y, Nemoz CJ, Baulieux J et al. Influence of the interval between preoperative radiation therapy and Surgery on downstaging and on the rate of sphincter-sparing Surgery for rectal cancer: the Lyon R90-01 randomized trial. J clin Oncol 1999; 17: 2396. Go to original source... Go to PubMed...
    33. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008; 248: 243-251. Go to original source... Go to PubMed...
    34. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009; 250: 582-589. Go to original source... Go to PubMed...
    35. Huntington CR, Boselli D, Hill JS, et al. Optimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: An analysis of the National Cancer Database (NCDB). 2015 ASCO Gastrointestinal Cancers Symposium. Abstract 510. Go to original source...
    36. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008; 26: 368-373. Go to original source... Go to PubMed...
    37. Folkesson J, Birgisson H, Pahlman L et al. Swedisch Rectal cancer Trial: long lasting benefits from radiotherapy on survival and local recurence rate. J Clin Oncol 2005; 23: 5644-5650. Go to original source... Go to PubMed...
    38. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 6386-6346. Go to original source... Go to PubMed...
    39. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal exciton for resectable rectal cancer: 12 year follow-up of multicentre, randomised controllled TME trial. Lancet Oncol 2012; 12: 575-582. Go to original source... Go to PubMed...
    40. Taylor FG, Quirke P, Heald RJ. For the MERCURY study group et al. Preoperative high-resolution magnetic resonance paging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, european study that recruited consecutive patiens with rectal cancer. Ann Surg 2011; 253: 711-719. Go to original source... Go to PubMed...
    41. Mathis KL, Larson DW, Dozois EJ, et al. Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg 2012; 99: 137-143. Go to original source... Go to PubMed...
    42. National Comprehensive Cancer Network (NCCN) Clinical Practise Guidelines in Oncology. Vers.2.2015.
    43. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatine followed by synchronous chemoradiation and total mesorectal exciton in magnetic resonance staging defined poor risk rectal cancer. J Clin Oncol 2006; 24: 668-674. Go to original source... Go to PubMed...
    44. Fernandet-Martos C, Pericay C, Aparicio J, et al. Phase II randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatine (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imagingdefinited, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865. Go to original source... Go to PubMed...
    45. Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the managemed of locally advanced rectal cancer. J Natl Compr Canc Netw 2014; 12: 513-519. Go to original source... Go to PubMed...
    46. Dvořák J, Veselý P, Tomšová M, et al. Retrospektivní studie k vyhodnocení výsledků léčby a určení prognostických faktorů u nemocných ozařovaných pro adenokarcinom rekta. Klin Onkol 2006; 19: 187-194.
    47. Baumann M, Grégoire V. Molecular-targeted agents for enhancing tumour response, s. 287-300. In: Joiner M, van der Kogel A: Basic Clinical Radiobiology. 4th ed. London, Edward Arnold, 2009: 375. Go to original source...
    48. Steele RJ, Kelly P, Ellul B, et al. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77: 1352-1354. Go to original source... Go to PubMed...
    49. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer. Cancer 1993; 71: 2454-2460. Go to original source... Go to PubMed...
    50. Khorana AA, Ryan CK, Cox C, et al.Vascular enndothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003; 97: 960-968. Go to original source... Go to PubMed...
    51. Azria D, Bibeau F, Barbier N, et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005; 5: 62. Go to original source... Go to PubMed...
    52. Shengjin L, Jae-Sung K, Jin-man K, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patiens treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 65: 705-712. Go to original source... Go to PubMed...
    53. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy. Radiother Oncol 2005; 74: 101-108. Go to original source... Go to PubMed...
    54. Kopp R, Rothbauer E, Ruge M, et al. Clinical implications of the EGF receptor ligand system for tumour progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003; 162: 115-132. Go to original source... Go to PubMed...
    55. Li S, Kim JS, Kim JM, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal cancer patiens treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 65: 1019-1028. Go to original source... Go to PubMed...
    56. Kim JS, Kim JM, Li S, al. Epidermal growth factor receptor as a predictor of tumour downstaging in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Cncol Biol Phys 2006; 66: 195-200. Go to original source... Go to PubMed...
    57. Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and post-treatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1455-1468. Go to original source... Go to PubMed...
    58. Zlobec I, Vuong T, Compton CC, et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008; 98: 450-456. Go to original source... Go to PubMed...
    59. Richter I, Dvořák J, Bartoš J. Neoadjuvatní chemoradioterapie karcinomu rekta v kombinaci s inhibitory receptoru pro epidermální růstový faktor. Klin Onkol 2014; 27: 166-172. Go to original source... Go to PubMed...
    60. Dvořák J, Sitorová V, Ryška A, et al. The prognostic significance of changes of tumour epidermal growth factor receptor expression after neoadjuvant chemoradiation in patiens with rectal adenocarcinoma. Strahlenter Onkol 2012; 10: 145-147. Go to original source... Go to PubMed...
    61. Richter I, Dvořák J, Blüml A, et al. Vliv předoperační chemoradioterapie na změnu exprese receptoru pro epidermální růstový faktor u pacientů léčených předoperační chemoradioterapií pro lokálně pokročilý karcinom rekta. Klin Onkol 2014; 27: 361-366. Go to original source... Go to PubMed...
    62. Richter I, Dvořák J, Bluml A, et al. The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp Oncol 2015; 19: 48-53. Go to original source... Go to PubMed...
    63. Mishani E, Abourbeh G. Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007; 7: 1755-1772. Go to original source... Go to PubMed...
    64. Šlampa P. Předoperační chemoradioterapie v kombinaci s bevacizumabem u karcinomu konečníku. Klin Onkol 2011; 24: 338-342. Go to PubMed...
    65. Resch G, De vries A, Ofner D, et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - a two stage phase II clinical trial. Radiother Oncol 2012; 102: 10-13. Go to original source... Go to PubMed...
    66. Dipetrillo T, Pricolo V, Lagares-Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J radiat Oncol Biol Phys 2012; 82:124-129. Go to original source... Go to PubMed...
    67. Zlobec I, Steele R, Compton CC. VEGF as predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005; 104: 2517-2521. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.